The high expression of KLF6-SV1 has been shown to correlate with poor survival in patients with prostate cancer (Narla et al., 2008), ovarian cancer (DiFeo et al., 2006b), lung cancer (DiFeo et al., 2008; Zhang et al., 2018), pancreatic cancer (Hartel et al., 2008), and hepatocellular carcinoma (Vetter et al., 2012). This evidence concerns the gene KLF6 and prostate carcinoma.